# Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

> **NCT03221166** · PHASE3 · TERMINATED · sponsor: **IRCCS Burlo Garofolo** · enrollment: 9 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT03221166
- **Lead sponsor:** IRCCS Burlo Garofolo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-27
- **Primary completion:** 2020-07-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Difficulty in recruiting subjects who meet the inclusion/exclusion criteria
- **Last updated:** 2020-09-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221166, "Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03221166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*